Quince Therapeutics, Inc. (QNCX)

0.9851 +0.0251 (+2.61%) At close: 04:00PM EDT

Quince Therapeutics, Inc.

611 Gateway Boulevard
Suite 273
South San Francisco, CA 94080
United States
415-910-5717
https://www.quincetx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 32

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Dirk Thye M.D.	CEO, Chief Medical Officer & Director	856.5k	N/A	1970
Dr. Charles S. Ryan J.D., Ph.D.	President	524.47k	N/A	1964
Mr. Brendan Hannah M.B.A.	Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer	607.5k	N/A	1986
Dr. Guenter R. Janhofer M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Stacy Roughan	Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Mary Ellen Sillivos	Vice President of Human Resources	N/A	N/A	N/A
Dr. Stewart A. Low Ph.D.	Head of Discovery	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Corporate governance

Quince Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.